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Osteocytes, >90% of the cells in bone, lie embedded within the
mineralized matrix and coordinate osteoclast and osteoblast activ-
ity on bone surfaces by mechanisms still unclear. Bone anabolic
stimuli activate Wnt signaling, and human mutations of compo-
nents along this pathway underscore its crucial role in bone accrual
and maintenance. However, the cell responsible for orchestrating
Wnt anabolic actions has remained elusive. We show herein that
activation of canonical Wnt signaling exclusively in osteocytes
[dominant active (da)βcatOt mice] induces bone anabolism and
triggers Notch signaling without affecting survival. These features
contrast with those of mice expressing the same daß-catenin in
osteoblasts, which exhibit decreased resorption and perinatal
death from leukemia. daßcatOt mice exhibit increased bone mineral
density in the axial and appendicular skeleton, and marked in-
crease in bone volume in cancellous/trabecular and cortical com-
partments compared with littermate controls. daßcatOt mice display
increased resorption and formation markers, high number of osteo-
clasts and osteoblasts in cancellous and cortical bone, increased
bone matrix production, and markedly elevated periosteal bone
formation rate. Wnt and Notch signaling target genes, osteoblast
and osteocyte markers, and proosteoclastogenic and antiosteoclas-
togenic cytokines are elevated in bones of daßcatOt mice. Further,
the increase in RANKL depends on Sost/sclerostin. Thus, activation
of osteocytic β-catenin signaling increases both osteoclasts and
osteoblasts, leading to bone gain, and is sufficient to activate the
Notch pathway. These findings demonstrate disparate outcomes of
β-catenin activation in osteocytes versus osteoblasts and identify
osteocytes as central target cells of the anabolic actions of canon-
ical Wnt/β-catenin signaling in bone.
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Bone formation by osteoblasts is coupled to bone resorptionby osteoclasts. The proper balance between these two op-
posing processes is essential for bone health, and disruption of
this balance favoring resorption causes osteopenia and eventu-
ally osteoporosis, a devastating disease that affects millions
worldwide (1). Osteocytes, terminally differentiated osteoblasts
embedded in the mineralized bone matrix that constitute more
than 90% of all bone cells, control the generation and activity of
osteoblasts and osteoclasts by mechanisms still unraveling (2, 3).
The Wnt signaling pathway has emerged as a key regulator of
bone homeostasis (4). Wnt signaling controls developmental and
postnatal processes including cell proliferation, differentiation,
polarity, and migration through canonical and noncanonical
pathways (5). β-Catenin is the obligatory transducer for canoni-
cal Wnt signaling. Upon binding to Frizzled receptors and the
low-density lipoprotein receptor-related proteins (Lrp) 5 or 6,
Wnt ligands stabilize β-catenin, which translocates to the nucleus
and interacts with the transcription regulator Tcf/Lef to activate
transcription of Wnt target genes. The importance of canonical
Wnt/β-catenin (heretofore refer to as β-catenin) signaling in bone
homeostasis was discovered through loss- and gain-of-function
mutations in Lrp5, which induce, respectively, osteoporosis-pseu-
doglioma and high bone density syndromes (6–8). β-Catenin sig-
naling exerts cell context-dependent functions on osteoblastic cells
depending on the stage of differentiation. At early stages, β-catenin
inactivation in mesenchymal progenitors and osteoblast-committed
precursors arrests osteoblast differentiation leading to absence of
bone and lack of mature osteoblasts, respectively (9–12). At later
stages, however, β-catenin inactivation in mature osteoblasts/
osteocytes or only in osteocytes appears not to affect osteoblast
differentiation or bone formation, but instead increases osteoclast
differentiation and bone resorption leading to low bone mass
(13–15). Conversely, activation of β-catenin in osteoblasts leads
to increased bone mass by reducing bone resorption, again
without apparent effect on osteoblast production (4, 13). Fur-
ther, β-catenin activation in osteoblasts induces Notch signaling-
dependent alterations of hematopoiesis, leading to anemia, myeloid
lineage expansion, the development of acute myeloid leukemia,
and perinatal death (16).
Even when genetic manipulations of β-catenin signaling in
osteoblasts alter osteoclasts and bone resorption without de-
monstrable effects on osteoblasts or bone formation, the path-
way is linked to bone anabolism. Thus, recognized stimulators of
bone formation, such as parathyroid hormone and mechanical
loading, down-regulate the osteocytic Sost gene and increase
β-catenin signaling (17–22). Sost encodes the protein sclerostin,
a potent inhibitor of bone formation, which antagonizes Wnt
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signaling by binding to Lrp5/6. Lack of sclerostin expression is
responsible for the high-bone-mass/high-bone-formation human
diseases van Buchem and sclerosteosis (23–26). Mutations of the
Lrp5 gene that render a protein unable to be inhibited by scle-
rostin and/or Dkk1, another Wnt antagonist, also induce high
bone mass because of high bone formation (27, 28). These
findings raise the possibility that the cells responsible for the
anabolic outcomes of β-catenin signaling are not the less-mature
cells of the osteoblastic lineage that have been targeted by the
genetic manipulations. We addressed here the possibility that,
instead, osteocytes, the most differentiated cells of the lineage,
mediate anabolic actions of the pathway. We generated a novel
osteocyte-specific knock-in mouse model expressing a dominant
active (da) β-catenin in osteocytes (daßcatOt) and show that ac-
tivation of β-catenin signaling in osteocytes increases bone
remodeling with a positive balance in favor of bone formation
resulting in bone gain. This phenomenon is due to full stimula-
tion of osteoblast/osteocyte differentiation, leading to more bone
matrix producing osteoblasts and more osteocytes, together with
increased osteoclasts resulting from a Sost/sclerostin-dependent
stimulation of RANKL gene expression. Further, activation of
osteocytic β-catenin signaling is sufficient to enhance compo-
nents of the Notch signaling pathway, but it did not alter he-
matopoiesis or survival. These findings demonstrate disparate
outcomes of β-catenin activation in osteocytes versus osteoblasts
and identify the osteocyte as a central target cell of the anabolic
actions of canonical Wnt/β-catenin signaling in bone.
Results
Activation of β-Catenin in Osteocytes Increases Bone Mineral Density
and Cancellous Bone Volume. Knock-in daßcatOt mice expressing
dominant active β-catenin in osteocytes as demonstrated by
Western blotting (Fig. 1A) and immunohistochemistry (Fig. 1B
and Fig. S1A) exhibited up-regulation of canonical Wnt target
genes compared with control littermates Catnblox(ex3)/+ (Fig. 1C).
daßcatOt mice displayed no gross skeletal abnormalities at birth,
as evidenced by normally formed bone and cartilage (Fig. 1D).
After weaning, daßcatOt mice failed to grow at the same rate
than littermate controls, with a 20–50% lower body weight. At 6
mo, daßcatOt mice displayed smaller body size (Fig. 1E) and 20%
lower femoral length (12.8 ± 0.9 versus 15.9 ± 0.8 mm for lit-
termate controls). However, no differences in growth plate
thickness were found at either 2 or 4 mo of age (Fig. 1I and Fig.
S2). Circulating PTH was increased and calcium was decreased
in 2-mo-old daßcatOt mice, but both were normal in 4-mo-old
mice (Fig. S3A). No changes in phosphate were detected.
Longitudinal analysis showed progressive increase in bone
mineral density (BMD) in daßcatOt mice compared with controls
(Fig. 1F). At 4 mo of age, both female and male daßcatOt mice
exhibited a similar increase in total, spinal, and femoral BMD (Fig.
1G). X-ray radiography showed denser femoral, tibial, and verte-
bral bones in daßcatOt mice compared with controls (Fig. 1H). Von
Kossa or Goldner’s trichrome staining showed more mineralized
bone in the distal femur of daßcatOt mice (Fig. 1I and Fig. S2 B and
C). Microcomputed tomography (μCT) analysis of the distal femur
revealed more cancellous bone (Fig. 1J) and increased bone vol-
ume and trabecular number by eightfold and sixfold, respectively,
and markedly decreased trabecular separation, and increased tra-
becular thickness at 4 mo of age (Fig. 1K). Histomorphometric
analysis confirmed these findings at both 2 and 4 mo of age, albeit
trabecular thickness was not increased (Fig. 1L).
Osteocytic Activation of β-Catenin Unexpectedly Increases Bone
Resorption. Although eruption of the lower incisors was not
complete, daßcatOt mice exhibited full eruption of upper incisors
and molars (Fig. 2A) and displayed a threefold and twofold in-
crease in circulating levels of C-telopeptide fragments of type I
collagen (CTX), a marker of bone resorption, at 2 and 4 mo of
age, respectively, compared with control littermates (Fig. 2B).
Abundant osteoclasts were found in bones of daßcatOt mice, as
detected by osteoclast-specific TRAPase staining and quantified
for both 2- and 4-mo-old mice (Fig. 2 C–F). In cancellous bone
of the distal femur, osteoclast number per tissue area was in-
creased by two- to threefold in daßcatOt mice compared with
controls (Fig. 2C). However, osteoclast number and surface
normalized per bone surface was not different between geno-
types, likely due to the remarkable increase in cancellous bone
surface in the daßcatOt mice. On the femoral endocortical sur-
face, osteoclast number and surface were also markedly in-
creased by sixfold and eightfold, respectively, but only at 4 mo of
Fig. 1. Osteocytic activation of β-catenin increases Wnt signaling in bone,
and elevates bone mineral density and cancellous bone volume. (A) Western
blotting for dominant active (da) and wild-type (wt) β-catenin in long bone
lysates of control (c) and daßcatOt (da) mice (2-mo-old). (B) Immunohisto-
chemistry for β-catenin in osteocytes from distal femur. (C) qPCR for ca-
nonical Wnt target genes using lumbar vertebrae (L4) mRNA (2-mo-old).
*P < 0.05 by t test, n = 6–9 mice. (D) Whole-mount skeletal staining of
newborn pups; bone (red) and cartilage (blue). Ruler in millimeters. (E)
Control and daßcatOt male mice (6-mo-old). BMD of female mice (F) and of
male and female mice (4-mo-old) (G). *P < 0.05 by two-way ANOVA, n = 7–10
mice. f, femoral; s, spinal; t, total. (H) X-rays of hindlimbs. (I) Von Kossa/
Toluidine blue staining of distal femur longitudinal sections from 4-mo-old
mice. (J) Representative μCT cross-sectional reconstructed images of distal
femur of 4-mo-old mice. BV/TV, and trabecular number (Tb.N.), separation
(Tb.Sp.), and thickness (Tb.Th.) were measured by μCT in 4-mo-old mice (K)
and histomorphometry in 2- and 4-mo-old mice (L). *P < 0.05 by t test, n = 4
mice. (Scale bars: B, 25 μm; H, 2 mm; I and J, 0.5 mm.)

















age (Fig. 2 D and E). Further, osteoclasts were increased within
cortical bone from daßcatOt mice at 2 or 4 mo of age (Fig. 2F).
This effect led to 21-fold and 35-fold increases in intracortical
porosity compared with control littermates at 2 and 4 mo of age,
respectively (Fig. 2F). No difference between genotypes was
detected in the surface of individual osteoclasts (Fig. 2G), or in
the number of osteoclasts on the periosteal surface (Fig. 2H).
The increased resorption exhibited by daßcatOt mice contrasts
with the previously reported phenotype of mice expressing the
same daβ-catenin in osteoblasts using the Col1-2.3kb-Cre mice,
which lack tooth eruption, die after weaning, and exhibit low
bone resorption and osteopetrosis (13).
Osteocytic Activation of β-Catenin Increases Cortical Bone, Osteoblast
Number, and Bone Formation. The osteoblast marker alkaline
phosphatase was increased in plasma of both 2- and 4-mo-old
mice (Fig. 3A). Procollagen type 1 amino-terminal propeptide
(P1NP), a bona fide bone formation marker, was also elevated
in 2-mo-old mice (Fig. 3B). μCT showed more bone in cross-
sections at the femoral diaphysis with enlarged diameter in daßcatOt
mice compared with controls at 4 mo (Fig. 3C). Quantification
demonstrated an increase of 4.7-, three-, and twofold in peri-
osteal perimeter, cortical bone area and tissue area, resulting in
Fig. 2. Osteocytic activation of β-catenin increases bone resorption. (A) X-
ray of the head showing eruption of upper incisors (red arrow) in daßcatOt
mice (1-mo-old). (B) Plasma CTX levels, n = 8–14 mice. *P < 0.05 by t test.
(C–H) Histomorphometric quantification of TRAPase-stained osteoclasts in
longitudinal sections of distal femur (2- and 4-mo-old mice). (C) Microscopy
images of osteoclasts on cancellous bone of 4-mo-old mice. Areas a and b are
magnified on the right. Osteoclast number normalized to tissue area (N.Oc/
T.Ar) or to bone surface (N.Oc/BS), and osteoclast surface normalized to
bone surface (Oc.S/BS). (D) Microscopy images showing osteoclasts on
endocortical and intracortical bone surfaces of distal femur of 4-mo-old
mice. Arrows point at periosteal surface. Areas c and d are magnified on the
right. (E) Endocortical osteoclast number (N.Oc) and surface (Oc.S) normal-
ized by bone surface (BS). (F) Intracortical osteoclast number normalized to
cortical bone area (N.Oc/Ct.Ar) and percent porosity. (G) Average surface
occupied by individual osteoclast on cancellous, endocortical, and intra-
cortical bone. (H) Osteoclast number on periosteal bone surface (N.Oc/BS).
*P < 0.05 by t test, n = 3 mice for (C–H). (Scale bars: C, Left, 0.5 mm; C, Right,
0.1 mm; D, Left, 0.2 mm; D, Right, 0.05 mm.)
Fig. 3. Osteocytic activation of β-catenin increases periosteal bone forma-
tion and cortical bone. (A and B) Plasma levels of alkaline phosphatase and
P1NP, n = 8–11 mice; *P < 0.05 by t test. (C) Representative reconstructed
μCT images of cross-sectional femoral bone at the location indicated with
the red line (4-mo-old). Periosteal perimeter, bone area (BA), tissue area
(TA), BA/TA, and cortical porosity are shown. (D) Dynamic histomorpho-
metric analysis on periosteal bone surfaces. Representative images of fluo-
rochrome incorporation at the periosteal surface. (Scale bars: 0.1 mm.) BFR/
BS, bone formation rate per bone surface; MAR, mineral appositional rate;
MS/BS, percent mineralizing bone surface per bone surface. *P < 0.05 by t
test, n = 7 mice per genotype.
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increased BA/TA (Fig. 3C). Consistent with the findings in the
distal femur (Fig. 2F), daßcatOt mice also exhibited a remark-
able 150-fold increase in cortical porosity at the femoral di-
aphysis (Fig. 3C).
Dynamic bone histomorphometric analysis demonstrated
higher bone formation rate (BFR/BS) on the periosteal surface
at both 2 and 4 mo of age (Fig. 3D). This effect resulted from
combined higher mineral appositional rate (MAR) and miner-
alizing surface per bone surface (MS/BS), reflecting increased
individual osteoblast activity and more osteoblasts covering the
bone surface, respectively.
Consistent with the elevated bone formation on the periosteal
surface, osteoblast number per tissue area was increased in
cancellous bone (Fig. 4A) and on the femoral endocortical sur-
face (Fig. 4B) of daßcatOt mice at 2 and 4 mo of age. In contrast
to the periosteal surface, however, dynamic histomorphometric
analysis failed to demonstrate greater BFR on these surfaces.
Instead, in cancellous bone, BFR/BS was not changed at 2 mo of
age but was lower at 4 mo of age because of lower MAR (Fig.
S4A). On the endocortical surface, MAR is lower at both 2 and 4
mo, and MS/BS is lower at 4 mo; consequently, BFR/BS is lower
at both time periods. It is possible that the significantly lower
endocortical MS/BS at 4 mo is due to the higher N.Oc/BS and
Oc.S/BS that occurs at 4 mo but is not present at 2 mo (Fig. S4B).
At 4 mo of age for cancellous surfaces and at both ages for the
endocortical surface, reduced BFR was associated with signifi-
cantly less surface covered by double labels and more single-
labeled surface (Fig. S4 C and D). In addition, there was
a preferential loss of the first (green) label compared with the
second (red) label on both bone surfaces at 4 mo of age (Fig.
S4E). Moreover, both green and red labels displayed consider-
able thinning compared with the strongly fluorescent and wide
labels exhibited by the littermate controls (Fig. S4 C and D).
However, bone matrix formation was not impaired, as demon-
strated by the marked accumulation of osteoid revealed with two
special staining procedures that discriminate nonmineralized
from mineralized bone matrix (Fig. 4C and Fig. S2 B and C).
Quantification of von Kossa-stained sections showed a marked
increase in osteoid volume in cancellous bone of the distal femur
and cortical bone of the diaphysis, at 2 and, to a lesser extent, at
4 mo of age (Fig. 4C and Fig. S3B). More osteoid together with
lower MAR resulted in elevated mineralization lag time on
cancellous surfaces at 2 mo, and on the endocortical surface at
both ages (Fig. 4D). Further, osteocyte density was increased at
both ages in the cancellous compartment and the diaphysis (Fig.
4E). In contrast, neither osteoid volume nor osteocyte density
was different from controls in the cortical bone of the distal fe-
mur (Fig. 4 C and E and Fig. S3B). The combination of increased
resorption and accumulation of osteoid explains the lack of in-
creased BMD at 2 mo of age, even when circulating P1NP,
periosteal BFR, and cancellous/endocortical osteoblast number
and osteoid volume are increased. At 4 mo of age, the increase in
osteoid volume in daßcatOt mice lessened, demonstrating that
osteoid eventually mineralizes. Accordingly, BMD at 4 mo is
higher than in controls and the difference in BMD accentuates at
6 mo of age (Fig. 1 F and G).
Osteocytic Activation of β-Catenin Signaling Increases Osteoblast/
Osteocyte Differentiation and Proosteoclastogenic Cytokine Expression.
No changes in the proliferation marker PCNA or in the preva-
lence of osteoblast apoptosis were detected (Fig. S3 C and D). In
contrast, and consistent with the tissue and cellular phenotype,
markers of osteoblasts and osteocytes were elevated in bones of
daßcatOt mice. Expression of the osteoblast transcription factors
Runx2 and Osterix, as well as alkaline phosphatase and osteo-
calcin, was increased with no changes in collagen 1 (Fig. 5A), and
expression of the osteocyte marker Sost and of DMP1, Dkk1, and
MEPE expressed by osteoblasts and osteocytes was also elevated
(Fig. 5B). This evidence combined with the higher osteocyte
density (Fig. 4E) indicates that osteoblasts differentiate faster to
produce more osteocytes. Further, the prevalence of sclerostin-
positive osteocytes is higher in all bone envelopes of the daßcatOt
mice compared with controls (Fig. 5C and Fig. S1B), even in the
diaphysis in which approximately one-half of the bone is not
mineralized (osteoid) (Fig. 4C). Because sclerostin is a marker of
fully differentiated osteocytes embedded in mineralized bone, this
evidence is consistent with accelerated osteocyte maturation.
Similar to mice with β-catenin activation in osteoblasts/osteocytes
(13), OPG expression in daßcatOt mice was higher than controls
(approximately fourfold) (Fig. 5D). However, RANKL expres-
sion was even higher (>ninefold), resulting in increased RANKL/
OPG ratio. The expression of the mitogen for osteoclast pre-
cursors macrophage colony stimulating factor (M-CSF) was
also elevated. Increased M-CSF and RANKL/OPG ratio ex-
plain the elevated osteoclasts and bone resorption exhibited by
daßcatOt mice. mRNA expression of the osteoclast markers
cathepsin K (Ctsk), TRAP, calcitonin receptor, and RANK was
not changed or even decreased in bones from daßcatOt mice of
the axial and appendicular skeleton at both 2 and 4 mo of age
(Dataset S1). Because abundant TRAP-positive osteoclasts are
detected in bone and CTX is increased in the circulation, this
paradox could be explained by the fact that the cellular pop-
ulation in the daßcatOt bones is dominated by osteocytes/
osteoblasts masking the increase in osteoclastic gene expression.
Fig. 4. Osteocytic activation of β-catenin increases osteoblast number, os-
teoid production, and osteocyte density in cancellous and cortical bone.
Static histomorphometric analysis was performed in femoral cancellous and
cortical bone of 2- and 4-mo-old mice. (A and B) Osteoblast number per
tissue area (N.Ob/T.Ar) and per bone surface (N.Ob/BS). (C) Osteoid volume
per bone volume (OV/BV) and representative images of longitudinal sections
of femoral bone stained by von Kossa/McNeal (bone black and osteoid light
blue) or Goldner’s trichrome (bone green and osteoid orange/red) to dis-
criminate mineralized bone from osteoid are shown. (Scale bars: 25 μm.) (D)
Mineralization lag time calculated as osteoid thickness divided by MAR. (E)
Osteocyte density (N.Ot/B.Ar), *P < 0.05 by t test, n = 7 mice per genotype.

















To address the possibility that activation of β-catenin in
osteocytes increases RANKL via a Sost/sclerostin-dependent
mechanism, RANKL expression was analyzed in mouse models
with altered Sost expression. DMP1-Sost transgenic mice
overexpressing Sost in osteocytes exhibited increased RANKL
expression, and the expected decreased in the expression of
OPG and other Wnt target genes (22) (Fig. 5E). Furthermore,
Sost knockout mice exhibited the expected increase in OPG but
no changes in RANKL expression (Fig. 5F). These results
demonstrate that Sost overexpression is sufficient to increase
RANKL, and it is needed to increase RANKL by Wnt activa-
tion. Moreover, as in vivo in the daßcatOt mice, activating Wnt
signaling ex vivo (by blocking secreted sclerostin with a neu-
tralizing antibody; ref. 29) increased mRNA expression for
OPG and RANKL in bone organ cultures from WT mice or
from control Catnblox(ex3)/+ mice (Fig. 5G). However the anti-
sclerostin antibody did not alter the already elevated expression
of OPG but reversed to control levels the increased expression
of RANKL in bones from daßcatOt mice, demonstrating that
increased RANKL induced by osteocytic activation of β-catenin
requires sclerostin function. Taken together, these findings
demonstrate that β-catenin activation increases OPG in all cells
of the osteoblastic lineage, whereas it only increases RANKL in
osteocytes that also express Sost/sclerostin.
Notch Signaling Lies Downstream of β-Catenin Activation in Osteocytes.
Cross-talk between the Wnt and Notch signaling pathways has
been shown through the regulation of Notch ligands by β-cat-
enin signaling (30–33). Consistent with this evidence, bones
of daßcatOt mice exhibited higher levels of mRNA expression
for Notch ligands, Notch receptors, and Notch target genes (Fig.
6 A–C and Dataset S1). Although slight changes in the gene
expression profile were found at 2 versus 4 mo of age and in
bones of the axial or appendicular skeleton, overall mRNA
expression of all components of the Notch signaling pathway
was increased in daßcatOt mice. Moreover, the expression of the
Notch target gene Hes 1 at the protein level was increased in
osteocytes in long bones (Fig. 6D).
In contrast to recent findings in mice with β-catenin activation
in osteoblasts that exhibit Jag1-dependent expansion of myeloid
cells leading to leukemia, anemia, and perinatal death (16), the
increased Notch ligand/receptor/target gene expression induced
by osteocytic activation of β-catenin did not cause premature
death (Fig. 6F) or splenomegaly, with only minimal changes in
spleen weight (Fig. 6G). Moreover, hematocrit and the number
of red blood cells were normal (Fig. 6H); there was no throm-
bocytopenia and, instead, platelet number was slightly increased
(Fig. 6I). Further, no changes were found in the overall white
blood cell count, or in the number of neutrophils, lymphocytes,
or monocytes (Fig. 6J). Thus, daßcatOt mice do not exhibit he-
matological changes consistent with anemia or leukemia in
young (1.5-mo-old) or adult (4-mo-old) mice.
Discussion
Bone anabolic stimuli activate canonical Wnt/β-catenin signaling,
and human mutations of components along this pathway un-
derscore its crucial role in bone accrual and maintenance by
stimulating bone formation. Paradoxically, however, genetic ac-
tivation of β-catenin signaling in bone forming osteoblasts and
their progenitors decreases osteoclasts and bone resorption,
without apparent effects on bone formation. The current study
demonstrates that, in contrast, activation of this pathway exclu-
sively in osteocytes—terminally differentiated cells of the oste-
oblastic lineage—is sufficient to induce bone anabolism. These
findings identify the osteocyte as a central target cell of the bone
anabolic actions of β-catenin signaling. Because osteocytes are
long-lived and constitute more than 90% of bone cells, they
represent a more-effective target than scarce, short-lived osteo-
blasts, in the quest toward the development of better treatments
for osteoporosis and other bone-related disorders.
The findings reported here challenge the current paradigm
that β-catenin signaling in osteoblastic cells only regulates bone
resorption, without affecting bone formation (13–15). Mice
lacking β-catenin in osteoblast precursors, osteoblasts, or osteo-
cytes, indeed, display severe osteopenia because of decreased
OPG and exacerbated bone resorption (13–15, 34). However,
MAR and BFR are decreased upon conditional deletion of
β-catenin from osteoblast precursors in 2-mo-old mice (34). In
addition, mice with β-catenin haploinsufficiency in osteocytes
display a defective anabolic response to bone loading (35). These
pieces of evidence have suggested a role for β-catenin signaling in
osteoblastic cells controlling osteoblast activity. However, a di-
rect demonstration of bone anabolism was missing. The current
report demonstrates that β-catenin activation selectively in
osteocytes leads to bone gain, proving that osteocytes are the
cells of the osteoblastic lineage that enable bone anabolism in
response to β-catenin signaling. These findings strongly suggest
that osteocytes also might mediate anabolism induced by sys-
temic activation of the pathway, with inhibitors of GSK3β or
neutralizing antibodies of sclerostin, or even in human mutations
of components of the Wnt pathway (4). The fact that osteocytes
comprise most of the cells in bone might explain why bone
anabolism is the most patent outcome of systemic Wnt activation,
Fig. 5. Osteocytic activation of β-catenin increases osteoblast and osteocyte
markers and proosteoclastogenic and antiosteoclastogenic cytokines. (A, B,
and D) Gene expression was quantified by qPCR in lumbar vertebrae (L4)
(2-mo-old). *P < 0.05 by t test, n = 6–9 mice. (C) The percentage of sclerostin-
positive osteocytes was quantified in longitudinal sections of femoral bone
stained with an anti-sclerostin antibody. *P < 0.05 by t test, n = 3 mice.
RANKL protein expression was detected by immunohistochemistry in lon-
gitudinal sections of distal femur of 4-mo-old mice. (E and F) OPG and
RANKL expression in mice overexpressing or lacking the Sost gene. (G) OPG
and RANKL expression induced by Wnt activation by treating bones from
5-wk-old wild type or 3-wk-old controls and daßcatOt mice with an anti-
sclerostin antibody. (Scale bars: C, 50 μm; D, 25 μm.)
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even when inhibition of resorption might be also manifested in
some instances (36).
Our findings also established unexpected facts regarding the
control of resorption by the β-catenin pathway. daßcatOt mice ex-
hibit tooth eruption, increased osteoclasts, and elevated resorption.
This aspect of the phenotype contrasts with the findings in mice
expressing the same dominant active β-catenin in osteoblasts,
which lack tooth eruption and exhibit reduced resorption. There-
fore, activation of β-catenin signaling in osteocytes versus in less
mature cells of the osteoblastic lineage leads to opposite effects on
resorption. Whereas in both cases OPG expression is increased,
in daßcatOt mice, RANKL expression is even higher, resulting in
elevated RANKL/OPG ratio. Previous studies showed no
changes in RANKL expression by either deletion or activation
of β-catenin in Col1-2.3kb–expressing cells or activation of the
pathway in osteocalcin-expressing cells in vivo (13). Hence,
a major difference between β-catenin activation in osteocytes
with these other models is the increased RANKL. Further, we
demonstrate now that increased RANKL is a consequence of
increased Sost expression in daßcatOt mice. Several pieces of
evidence support this mechanism. Overexpression of Sost is suf-
ficient to elevate RANKL expression, whereas Wnt signaling
Fig. 6. Osteocytic activation of β-catenin increases expression of ligands, receptors, and target genes of the Notch pathway, without affecting hematopoiesis
or life span. (A–D) Gene expression was quantified in lumbar vertebrae (L4) or long bones from 2- and 4-mo-old mice; n = 6–9 mice. (E) Hes 1 protein expression
was detected by immunohistochemistry in longitudinal sections of distal femur of 4-mo-old mice. (Scale bars: 25 μm.) (F) Mouse survival rate up to 6 mo of age;
n = 7–10 mice. (G) Spleen weights (2- and 4-mo-old). (H–J) Hematocrit and peripheral blood cell number (1.5- and 4-mo-old mice); n = 6–8. *P < 0.05 by t test.

















activation fails to increase RANKL in mice lacking the Sost gene.
Similar to these in vivo findings, activation of Wnt signaling
ex vivo enhances RANKL expression; furthermore, the increased
RANKL expression in bones from daßcatOt mice is abolished by
an anti-sclerostin antibody. Therefore, taken together with pre-
vious studies (13, 14), our findings demonstrate that β-catenin
activation increases OPG in all cells of the osteoblastic lineage,
whereas it only increases RANKL in osteocytes that also express
Sost. Our results are consistent with earlier studies demonstrating
that elevated expression of Sost/sclerostin up-regulates RANKL
(19, 37) and increases osteoclasts (37). Expression of M-CSF is
also elevated in daßcatOt mice, consistent with our recent findings
demonstrating that M-CSF is a downstream target of RANKL in
osteocytes (38). Thus, the combination of elevated RANKL and
M-CSF prevails over the increased expression of OPG, and re-
sorption is then elevated in daßcatOt mice. Comparison of the
phenotype of daßcatOt mice with that of mice in which β-catenin
was deleted from osteocytes (15) revealed another unforeseen
finding that both activation and deletion of β-catenin in osteocytes
leads to increased bone resorption. Expectedly, the canonical
Wnt/β-catenin target gene OPG is regulated in the opposite
manner in the two models, because its expression is increased by
activation and decreased by deletion of β-catenin in osteocytes.
However, whereas low OPG leads to increased resorption with
deletion of β-catenin, high OPG resulting from activation of the
pathway is surmounted by the even higher levels of RANKL and
M-CSF, and then resorption is also increased.
More osteoclasts in daßcatOt mice might explain the para-
doxical low MS/BS and BFR in the presence of more osteoblasts
on endocortical bone surfaces. The loss of double labels and the
presence of abundant, thin labels might be due to bone being
resorbed shortly after it is formed. Consistent with this hypoth-
esis, greater BFR could be readily detected on the periosteal
surface where there were not more osteoclasts. Further, low
MAR in the context of osteoid overproduction leads to longer
mineralization lag time and indicates a mismatch between the
high rate of bone matrix production and the relative low rate of
mineralization. Nevertheless, the accumulated osteoid eventually
mineralizes, resulting in a progressive increase in BMD.
Similar high bone mass and high bone turnover phenotype is
found in mice with activation of the PTH receptor in osteocytes
(18, 19, 38–40). Remarkably, however, the mechanisms un-
derlying the skeletal phenotypes of these two mouse models are
diametrically opposite. Indeed, with osteocytic PTH receptor
activation, Sost/sclerostin expression is decreased, whereas with
osteocytic β-catenin activation, Sost/sclerostin expression is in-
creased. Because Sost/sclerostin and OPG are both increased
instead of being decreased as expected with PTH elevation, it is
unlikely that the increased PTH levels found in 2-mo-old mice
contribute to the skeletal phenotype of the daßcatOt mice.
Notch signaling is activated by cell-to-cell communication
between membrane-bound ligands and receptors. Previous
studies in other cell types suggested that Notch activation lies
downstream of Wnt signaling (30–33). The present study dem-
onstrates that also in osteocytes, activation of β-catenin signaling
is sufficient to trigger Notch activation and to increase the ex-
pression of traditional Notch target genes. The expression of the
ligands Jag1 and 2 and Dll4, and the receptors Notch 1, 2, and 4
is also elevated in daßcatOt mice, raising the possibility that
osteocytic β-catenin initiates a chain of Notch activation throughout
the osteocyte network, by which signals are amplified in an
autocrine/paracrine fashion. Earlier studies demonstrated that
the effects of Notch signaling in the skeleton are complex and,
similar to Wnt signaling, are cell-context specific and dependent
on the stage of osteoblastic cell differentiation (41–44). In par-
ticular, activation of Notch signaling in osteocytes has a strong
impact on bone homeostasis, by mechanisms still unclear and
which appear to be different in cancellous versus cortical bone
(45). Mice with osteocytic activation of Notch exhibit increased
cancellous bone and elevated resorption with exacerbated po-
rosity in cortical bone (45). These features resemble the ones
exhibited by daßcatOt mice, raising the possibility that Notch
activation is responsible for some of the skeletal consequences of
activating osteocytic β-catenin.
β-Catenin activation in osteoblasts affects not only the skele-
ton, but also induces anemia and expansion of myeloid cells,
leading to leukemia and premature death by 6 wk of age (16).
This effect results from increased expression of Jag1 in osteo-
blasts, which triggers Notch signaling in hematopoietic stem cell
progenitors. In contrast to these findings, daßcatOt mice do not
exhibit hematological changes consistent with anemia or leuke-
mia, suggesting that in this case the elevated expression of Jag1
(and the other Notch ligands) does not activate Notch signaling
in cells of the hematopoietic lineage. The inability of Notch
ligands expressed in osteocytes to activate Notch signaling in
hematopoietic cells might be explained by the relatively re-
stricted access of osteocytes compared with osteoblasts to direct
cell-to-cell contact with hematopoietic cells under physiological
conditions. In contrast, osteocyte-osteocyte contact within the
lacunar-canalicular network provides the basis for Notch acti-
vation in osteocytes themselves, as evidenced by increased ex-
pression of Hes 1. Future studies, outside the scope of the
current work, are warranted to clarify the mechanism underlying
the differential target cells of Notch activation induced by con-
stitutive activation of β-catenin along the osteoblastic lineage.
The consequences of Sost up-regulation for bone anabolism
observed in daßcatOt mice are not fully understood. However,
elevated Sost/sclerostin expression might temper the anabolic
response in older mice to protect them from excessive bone gain.
In fact, the increase in circulating P1NP, periosteal bone for-
mation, and osteoid volume in daßcatOt mice is smaller at 4 mo
of age than at 2 mo of age. A similar mechanism recently has
been proposed for the attenuation of the anabolic response to
administration of an anti-sclerostin antibody (46).
β-Catenin is the molecular mediator of canonical Wnt sig-
naling, thus examining the consequences of its activation is
a powerful approach to uncover the role(s) of canonical Wnt
signaling in osteocytes. However, it is important to note that our
model is not entirely equivalent to activation of canonical Wnt
signaling by a ligand, which would also activate receptor-medi-
ated events upstream of β-catenin and trigger the pathway in
other cells besides osteocytes. Further, our model also differs
from signal transduction activated by Wnt ligands, which might
involve canonical and noncanonical signaling pathways.
In conclusion, our study dissects desired (bone gain) from
undesired (decreased resorption and leukemia) outcomes by
selective activation of canonical Wnt/β-catenin signaling in osteo-
cytes versus osteoblasts.
Materials and Methods
Mice. daßcatOt mice were generated by crossing DMP1-8kb-Cre mice, which
express Cre recombinase in osteocytes, but not in osteoblasts (47), with
Catnblox(ex3) mice, in which exon 3 that encodes for the sites required for
β-catenin degradation is flanked by LoxP sites (48). Hemizygous DMP1-8kb-
Cre+/− mice were crossed with homozygous Catnblox(ex3)/lox(ex3) mice. The
cross rendered 50% Catnblox(ex3)/+;DMP1-8kb-Cre+/− (named daßcatOt mice)
and 50% controls Catnblox(ex3)/+ mice. Generation and characterization of
DMP1-8kb-Cre mice was published (47). DMP1-8kb-Cre mice are of C57BL/6
background, are born at the expected Mendelian frequency, both males and
females are fertile, and exhibit normal size and weight. DMP1-8kb-Cre mice
are maintained as hemizygous (DMP1-8kb-Cre+/−). The skeletal phenotype
of the DMP1-8kb-Cre mice is indistinguishable from the wild-type C57BL/6
mice or from the Catnblox(ex3)/+mice used as littermate controls in the current
study. Mice were fed with wet regular diet (Harlan), received water ad libi-
tum, and were maintained on a 12-h light/dark cycle. All animal procedures
were approved by the Institutional Animal Care and Use Committee of
Indiana University School of Medicine.
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Analysis of Skeletal Phenotype. Radiographs of mouse skeleton were gen-
erated by using a Pixarray 100 (Bioptics) with 1-s exposure under 45 kV. BMD
measurement and micro-CT analysis were performed as described (19, 22).
Mice were anesthetized via inhalation of 2.5% (vol/vol) isoflurane (Abbott
Laboratories) mixed with O2 (1.5 L/min), and BMD of the total body, ex-
cluding the head and the tail, the lumbar spine (L1–6), and the femur was
measured by dual energy X-ray absorptiometry (DXA) by using a PIXImus II
densitometer (GE Medical Systems) in mice at 1, 2, 4, and 6 mo of age. For
micro-CT analysis, bones from 4-mo-old mice were dissected, cleaned off soft
tissue, fixed in 10% buffered formalin, and stored in 70% ethanol until
scanned at 6-μm resolution (Skyscan 1172; SkyScan).
Serum Biochemistry. Plasma was obtained from blood from the facial vein of
mice after 3-h fasting at the indicated age. P1NP and CTX were measured by
using ELISA kits (Biomedical Technologies and Immunodiagnostic Systems),
respectively (41, 42, 49). Alkaline phosphatase was measured on a Randox
Daytona analyzer (Randox Laboratories Limited) at the General Clinical Re-
search Center of Indiana University School of Medicine. Parathyroid hor-
mone levels were measured in plasma by using a mouse PTH 1–84 ELISA Kit
(Immunotopics). Calcium measurement was performed at the General Clin-
ical Research Center of Indiana University School of Medicine by using
a Roche Cobas Mira S Chemistry analyzer (Roche Diagnostics).
Bone Histomorphometry. For dynamic bone histomorphometric analysis, mice
were injected with calcein (30 mg/kg; Sigma) and alizarin red (50 mg/kg;
Sigma) 7 and 2 d before killing, respectively, as described (19, 22). Bones were
dissected, fixed in 10% buffered formalin, and embedded in methyl meth-
acrylate. Thick (100-μm) cross-sections at the midshaft of the femurs were
prepared by using a diamond-embedded wire saw (Histosaw; Delaware Di-
amond Knives) and ground to a final thickness of approximately 40 μm. Thin
(5 μm) longitudinal sections at the medial distal femurs were cut by using
a diamond Automated Rotary Microtome Leica RM2255 (Leica Micro-
systems). Total, single, double, the first and the second labeled perimeter,
and interlabel width were measured. A value of 0.1 μm/d was used for
mineral apposition rate (MAR) when single labels were present, but double
labels were not detected (50). Mineralization lag time (Mlt) was calculated
by dividing osteoid thickness by MAR (51). For static bone histomorpho-
metric analysis, longitudinal sections of the distal femurs were stained for
TRAPase or von Kossa, and counterstained with Toluidine blue. Histo-
morphometric analysis was performed by using the OsteoMeasure High
Resolution Digital Video System (OsteoMetrics). Total bone volume (miner-
alized plus osteoid) was used when determining the effect of osteocytic
activation of β-catenin on Bone volume per tissue volume (BV/TV) and tra-
becular parameters. Analyses were performed in the cortical bone at the
femoral diaphysis and in the cancellous and cortical bone of an 800-μm re-
gion of the distal femur, starting 200 μm below the growth plate. Cortical
bone in the distal femur was defined as the bone between the periosteal
surface and the endocortical surface derived from the growth plate that
continues toward the diaphysis. We cannot exclude the possibility that
regions considered as cortical bone contain some trabeculae that formed as
outgrowths form the endocortical surface. Osteocyte density was also
evaluated in these three regions. Growth plate width was measured in von
Kossa/McNeal-stained sections of the distal femur by using the Osteomea-
sure software. Bone sections were also stained with Goldner’s trichrome
staining to visualize osteoid and mineralized bone. The terminology and
units used are those recommended by the Histomorphometry Nomenclature
Committee of the American Society for Bone and Mineral Research (51). The
percentage of apoptotic osteoblasts was determined in cancellous bone of
the distal femur by staining longitudinal femoral sections with Tdt-mediated
dUTP nick-end labeling (TUNEL) kit (EMD Millipore), as published (18).
Immunohistochemistry. The expression of the indicated proteins was visual-
ized in paraffin-embedded femora from 2- and 4-mo-old, as described (17, 18).
Briefly, sections were deparaffinized, treated with 3% H2O2 to inhibit endog-
enous peroxidase activity, blocked with rabbit or goat serum, and then in-
cubated with mouse monoclonal anti-CTNNB1 (β-catenin) antibody (1:100; BD
Biosciences); rabbit polyclonal anti-Hes1 antibody (1:500; Abcam); goat poly-
clonal anti-RANKL antibody (1:100; Santa Cruz Biotechnology), or goat poly-
clonal anti-mouse sclerostin antibody (1:100; R&D Systems). Sections were then
incubated with the corresponding biotinylated secondary antibody followed by
avidin conjugated peroxidase (Vectastain Elite ABC Kit; Vectora Laboratories).
Color was developed with a diaminobenzidine substrate chromogen system
(Dako Corp.). Cells expressing the protein of interest are stained in brown,
whereas negative cells are green-blue. Corresponding nonimmune IgGs were
used as negative controls. The prevalence of sclerostin-positive osteocytes was
assessed in cortical bone of the distal femur from 2-mo-old mice.
Quantitative PCR. Total RNA extraction and quantitative PCR (qPCR) were
performed as reported (22). Briefly, total RNA was extracted from lumbar
vertebrae L4 by using TRIzol (Invitrogen). cDNA was synthesized by using
high capacity cDNA reverse transcription kit (Applied Biosystems). Gene
expression was analyzed by qPCR using primer probe sets from Applied
Biosystems or from Roche Applied Science. Relative mRNA expression levels
were normalized to the housekeeping gene ribosomal protein S2 (ChoB) by
using the ΔCt method (19, 22).
Western Blotting. Western blotting was performed as described (22). Protein
lysates were prepared from femur/tibia diaphysis (∼1/3 of the bone). Ten
micrograms of protein were separated on a 10% SDS/PAGE and electro-
transferred to PVDF membrane (Millipore). Immunoblots were performed by
using goat polyclonal anti-mouse β-catenin antibody (1:1,000; R&D Systems),
or mouse monoclonal anti-PCNA (1:1,000) or anti-α-tubulinor anti-β-actin
(1:2,000) antibodies (Santa Cruz Biotechnology). Blots were developed by
using chemiluminescence (Pierce Biotechnology).
Ex Vivo Cultures. Calvarial bones and femora were harvested from 3- and
5-wk-old wild-type animals, and daßcatOt mice and littermate controls, and
maintained in α-MEM containing 10% FBS for 24 h. Bones were then treated
with an anti-sclerostin antibody (29) (10 μg/mL; Acris Antibodies) or vehicle
for 24 h, and mRNA was isolated. Gene expression was measured by qPCR, as
indicated above.
Hematological Measurements. Peripheral blood was collected by tail vein
bleeding by using Microvette collection tubes (Sarstedt 20.1278.100), and
blood cell count analysis was performed by using the Hemavet machine
(Drew Scientific).
Statistical Analysis. Data were analyzed by using SigmaStat (SPSS Science).
Differences between control and daßcatOt mice were evaluated by using
Student’s t test or two-way ANOVA for the comparison of factors age and
BMD, as indicated. A P value of 0.05 or lower was considered statistically
significant. All values are reported as the mean ± SDs.
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